MCL Literature Feed

In a real-world R/R MCL cohort, zanubrutinib demonstrated significantly longer overall survival versus ibrutinib and favorable trends versus acalabrutinib, guiding clinical selection of covalent BTKis.

The NAMPT inhibitor KPT-9274 sensitizes TP53-mutated MCL to alkylating chemotherapy by disrupting the DNA damage response, offering a novel combination strategy for this high-risk, chemo-resistant population.

A family history of hematological malignancy is associated with inferior event-free survival in mantle cell lymphoma, suggesting it may be a novel adverse prognostic factor.

Adding ibrutinib to intensive frontline immunochemotherapy for newly diagnosed, fit MCL patients aims to deepen responses and improve outcomes, often as induction before transplant consolidation.

Preclinical data shows that inhibiting the cell cycle regulator CDC20 suppresses MCL growth by downregulating the PI3K/AKT pathway, identifying CDC20 as a novel therapeutic target.

Zanubrutinib plus age-adapted bendamustine-rituximab induction followed by zanubrutinib maintenance demonstrates high efficacy (75% 2-year PFS) and deep responses (94% uMRD) in elderly, frontline MCL patients.

This Chinese real-world study characterizes the clinical features and poor prognosis of blastoid/pleomorphic MCL, providing data to help risk-stratify and manage this aggressive subtype.

This meta-analysis suggests zanubrutinib monotherapy yields superior complete and overall response rates over ibrutinib and acalabrutinib in relapsed/refractory MCL, informing optimal BTKi selection.

A novel preclinical compound dually inhibiting FLT3 and HDAC is developed, introducing a new potential therapeutic mechanism for hematologic malignancies, though its specific relevance to MCL is unknown.

This first comprehensive proteogenomic analysis of MCL demonstrates that integrating protein data with genomics improves survival prediction and identifies molecular subtypes linked to IGHV/CCND1 mutations, offering new prognostic tools.

A case of CD5+ cutaneous DLBCL highlights a diagnostic pitfall, as it can mimic MCL but is distinguished by cyclin D1 negativity, reinforcing the need for complete immunohistochemical workup.

In a large real-world cohort, brexu-cel demonstrated high efficacy in R/R MCL patients ≥70 years, indicating functional status, not chronological age, should determine CAR-T eligibility.

A novel liquid biopsy technique using cell-free chromatin profiling non-invasively tracks disease origin and monitors therapy response, offering a powerful new tool for MRD and biomarker discovery.

Proteomic profiling identified an MCL-specific protein signature, including seven targets missed by RNA analysis, offering novel avenues for CAR-T therapy and personalized treatment.

The oral AKT inhibitor capivasertib showed modest single-agent activity (30% ORR) in relapsed/refractory MCL, with PTEN deficiency emerging as a potential predictive biomarker for patient selection.

This large epidemiological study identifies mantle cell lymphoma as one of the most frequent and aggressive nodal non-Hodgkin lymphoma subtypes in North Africa, highlighting regional disease patterns.

A case report demonstrates repeated MCL progression upon initiation of the JAK-1 inhibitor upadacitinib for psoriatic arthritis, suggesting a potential role for JAK signaling in promoting MCL growth.

Bridging radiotherapy before CAR-T effectively controls disease in MCL patients, with most showing rapid tumor reduction and no local progression, supporting its use as a pre-CAR-T strategy.

This real-world study identifies key patient and systemic barriers limiting CAR-T therapy access for relapsed/refractory MCL, highlighting disparities between trial eligibility and clinical practice.

This large real-world study shows second primary malignancies in MCL patients double mortality risk versus non-MCL patients, mandating long-term surveillance for these subsequent cancers.

This review provides a treatment and sequencing algorithm for relapsed/refractory MCL, navigating the complex landscape of BTKi, BCL2i, CAR-T, bispecifics, and transplant for individualized patient care.

A distinct DNA demethylation signature in MCL tumors acts as a "fossil record" of early gene activation, offering a novel bioinformatic approach to understand the cancer's developmental origins.

This review summarizes how epigenetic dysregulation drives MCL pathogenesis, highlighting the potential for novel biomarkers and therapeutic targets based on mechanisms like DNA methylation and histone modification.

A new preclinical cell line and patient-derived xenograft model of a non-MCL lymphoma with a CCND1 rearrangement provides a tool to study the specific biological role of this key driver.

This longitudinal study reveals MCL acquires new high-risk genetic features after chemoimmunotherapy, explaining relapse and emphasizing the need for genomic profiling to guide subsequent therapies.

This case report details pleomorphic MCL presenting as life-threatening hemophagocytic lymphohistiocytosis (HLH), emphasizing the need for high clinical suspicion of this rare, sepsis-mimicking oncologic emergency.

This paper details a new UPLC-MS/MS method for rapid venetoclax plasma quantification, which could facilitate therapeutic drug monitoring to optimize dosing and toxicity management in MCL.

This case of MCL presenting as diffuse gastrointestinal polyposis mimicking hereditary syndromes underscores the need for histopathology to avoid misdiagnosis and ensure prompt immunochemotherapy for this rare presentation.

Undetectable MRD after induction chemotherapy identifies mantle cell lymphoma patients who may safely omit consolidative autologous stem cell transplant, enabling a personalized, de-escalation treatment strategy.

The CD19 CAR-T therapy relma-cel demonstrated high, durable responses (71% ORR, 18-month DOR) with manageable toxicity in heavily pretreated Chinese patients, establishing it as an effective option for relapsed/refractory MCL.